PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11194214-5	2001	RESULTS: Treatment with repaglinide significantly improved glycemic control with respect to baseline and placebo, reducing HbA1c by 1.14% from baseline and fasting plasma glucose by 1.8 mmol/l.	repaglinide	24-35	hemoglobin subunit alpha 1	Homo sapiens	123-127	
24843581-7	2012	The target HbA1c values of <6.9% were achieved by 75.0% of the repaglinide group vs 59.1% for nateglinide.	repaglinide	66-77	hemoglobin subunit alpha 1	Homo sapiens	11-15	
18505128-6	2008	RESULTS: Similar decreases in fasting blood glucose, 2 hours postprandial blood glucose, and HbA1 c were found in both nateglinide group and repaglinide group without significant differences.	repaglinide	141-152	hemoglobin subunit alpha 1	Homo sapiens	93-97	
15324515-4	2004	At the end of the study, changes in HbA1c from baseline were -1.28% points and -0.67% points for repaglinide/metformin and nateglinide/metformin, respectively.	repaglinide	97-108	hemoglobin subunit alpha 1	Homo sapiens	36-40	
11472451-8	2001	Change in HbA1c from baseline was significantly better with repaglinide than with glipizide after 12 months (P < 0.05).	repaglinide	60-71	hemoglobin subunit alpha 1	Homo sapiens	10-14	
17712875-12	2007	A mixed model analysis of variance on the 178 patients who started with combination therapy, either immediately or after a 3-6 month period on diet, showed that metformin plus gliclazide, repaglinide, or pioglitazone was associated with a gradual increase in HbA1c values.	repaglinide	188-199	hemoglobin subunit alpha 1	Homo sapiens	259-263	
10631622-3	2000	For the repaglinide treatment groups at the end of the study, changes in HbA1c from baseline values ranged from 1.8 to 1.9 percentage points lower than the placebo group.	repaglinide	8-19	hemoglobin subunit alpha 1	Homo sapiens	73-77	
9868989-10	1998	In other studies, repaglinide caused a decrease of 5.8 mmol x l(-1) in peak postprandial glucose levels, and a decrease of 3.1 mmol x l(-1) in fasting levels with a reduction in HbA1c of 1.8% compared with placebo.	repaglinide	18-29	hemoglobin subunit alpha 1	Homo sapiens	178-182